<DOC>
	<DOC>NCT00734734</DOC>
	<brief_summary>Trial for annual approval of interpandemic influenza vaccines</brief_summary>
	<brief_title>Safety and Immunogenicity of Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Key 65 years of age or older Mentally competent Willing and able to give written informed consent prior to study entry Able to comply with all the study requirements In general good health Key Any serious chronic or acute disease History of any anaphylactic reaction and/or serious allergic reaction following a vaccination, a proven hypersensitivity to any component of the study vaccine (e.g. to ovalbumin, chicken protein, chicken feathers, influenza viral protein, kanamycin and neomycin sulphate); Known or suspected (or have a high risk of developing) impairment/alteration of immune function (excluding that normally associated with advanced age) Receipt of parenteral immunoglobulin preparation, blood products and/or plasma derivates within the past 3 months and for the full length of the study; suspected or known HIV infection or HIVrelated disease A bleeding diathesis or condition associated with prolonged bleeding time that in the investigator's opinion would interfere with the safety of the subject Within the past 12 months, they have received more than one injection of influenza vaccine Within the past 6 months, participants had laboratory confirmed influenza disease; received influenza vaccine Within the past 4 weeks participants had received another vaccine; any investigational agent An acute exacerbation of a COPD (chronic obstructive pulmonary disease) within the past 14 days</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Prophylaxis of Influenza</keyword>
	<keyword>Influenza Vaccines</keyword>
	<keyword>MF59C.1</keyword>
</DOC>